Last updated: July 31, 2026
Nitrofurantoin macrocrystalline is a mature generic antibacterial used primarily for acute uncomplicated cystitis and, in selected cases, urinary-tract infection prophylaxis. The product has no meaningful originator exclusivity remaining in the United States. Commercial demand is stable but price-sensitive, with growth tied to urinary-tract infection incidence, antimicrobial-stewardship policies, generic supply reliability and continued susceptibility of common uropathogens. Clinical development is concentrated in comparative effectiveness, resistant urinary pathogens, prophylaxis and alternative dosing rather than new-drug registration.
What is nitrofurantoin macrocrystalline used for?
Nitrofurantoin macrocrystalline is an oral nitrofuran antibacterial. In the United States, the macrocrystalline capsule is marketed primarily as Macrodantin and by multiple generic manufacturers.
The FDA-approved indications for nitrofurantoin macrocrystalline include treatment of susceptible urinary-tract infections caused by organisms such as Escherichia coli, Enterobacter species, Klebsiella species, Enterococcus species and Staphylococcus saprophyticus. It is indicated for uncomplicated cystitis, not for pyelonephritis or systemic infection, because serum and renal-tissue concentrations are inadequate for upper-tract disease.[1]
How does macrocrystalline nitrofurantoin differ from Macrobid?
| Product |
Active ingredient |
Dosage form |
Typical adult regimen for acute cystitis |
Key distinction |
| Macrodantin and generics |
Nitrofurantoin macrocrystals |
25 mg, 50 mg and 100 mg capsules, depending on manufacturer |
50-100 mg four times daily for seven days under the legacy label |
Macrocrystalline formulation |
| Macrobid and generics |
Nitrofurantoin monohydrate/macrocrystals |
100 mg extended-release capsule |
100 mg twice daily for five days under the FDA label |
Combination formulation with modified release |
| Furadantin and generics |
Nitrofurantoin oral suspension |
25 mg/5 mL |
Weight-based dosing |
Liquid formulation |
The macrocrystalline formulation has historically required more frequent dosing than the monohydrate/macrocrystals formulation. This distinction affects prescription volume, adherence and substitution patterns.
What is the current clinical-trial status of nitrofurantoin?
Nitrofurantoin macrocrystalline is not in a conventional late-stage new-drug development program. Its clinical evidence base consists mainly of older randomized trials, observational studies, antimicrobial-resistance surveillance and contemporary studies comparing antibiotic strategies.
The current research questions are:
- Whether five-day or shorter regimens maintain efficacy in selected patients.
- How nitrofurantoin performs against resistant E. coli and other uropathogens.
- Whether nitrofurantoin remains suitable for patients with reduced renal function.
- How it compares with methenamine hippurate and other prophylactic strategies.
- How repeated exposure affects pulmonary, hepatic and neurologic toxicity.
- Whether local susceptibility patterns support continued empiric use.
What have recent comparative studies shown?
A major randomized trial, ALTAR, compared methenamine hippurate with daily low-dose antibiotic prophylaxis in women with recurrent urinary-tract infections. The antibiotic arm used clinician-selected agents, including nitrofurantoin, trimethoprim and cephalexin. Methenamine was found to be noninferior to antibiotic prophylaxis within the trial’s prespecified margin, supporting a broader role for non-antibiotic prevention in recurrent infection.[2]
ALTAR did not establish nitrofurantoin macrocrystalline as superior to other prophylactic antibiotics. Its commercial impact is indirect: increased use of methenamine and behavioral prevention may limit long-term prophylactic nitrofurantoin exposure, while acute cystitis treatment remains a separate demand segment.
The American College of Obstetricians and Gynecologists continues to recognize nitrofurantoin as an option for certain urinary infections during pregnancy, subject to gestational-age, glucose-6-phosphate dehydrogenase and clinical-risk considerations.[3]
What are the main safety issues in nitrofurantoin clinical development?
Nitrofurantoin’s safety profile limits chronic and high-risk use more than short-course cystitis treatment.
Pulmonary toxicity
Acute hypersensitivity pneumonitis and chronic pulmonary fibrosis are established risks. Chronic pulmonary toxicity is more strongly associated with prolonged prophylactic use, older age and cumulative exposure. Patients with cough, dyspnea or unexplained pulmonary findings require clinical evaluation and discontinuation may be necessary.[1,4]
Hepatic injury
Nitrofurantoin can cause acute or chronic liver injury, including autoimmune-like hepatitis. Chronic prophylaxis carries greater cumulative exposure risk than a single treatment course.[1,4]
Peripheral neuropathy
Peripheral neuropathy is uncommon but clinically important. Risk increases with renal impairment, diabetes, anemia, electrolyte abnormalities and prolonged exposure.
Renal function
The FDA label historically contraindicated use below a creatinine clearance threshold of 60 mL/min, while more recent geriatric and infectious-disease guidance commonly permits short-course use at lower renal function, often down to approximately 30 mL/min, when clinically appropriate.[1,5] Labeling, institutional policy and patient-specific risk assessment remain controlling factors.
What is the FDA regulatory status of nitrofurantoin macrocrystalline?
Nitrofurantoin macrocrystalline is an FDA-approved prescription antibacterial available through abbreviated new drug applications. It is not a new molecular entity, biologic or biosimilar product.
| Regulatory attribute |
Status |
| FDA pathway |
Abbreviated New Drug Application for generic products |
| Reference products |
Macrodantin and related nitrofurantoin macrocrystalline products |
| Prescription status |
Prescription-only |
| Primary indication |
Acute uncomplicated cystitis caused by susceptible organisms |
| Pediatric use |
Label-dependent, with age and formulation restrictions |
| Pregnancy |
Clinical-use decision depends on trimester, indication and patient risk |
| Renal impairment |
Restrictions vary by label and clinical guidance |
| Biosimilar pathway |
Not applicable |
| Orphan-drug status |
Not a principal commercial driver |
| New-drug exclusivity |
Expired |
FDA product labeling states that nitrofurantoin should not be used for pyelonephritis or perinephric abscess because it does not achieve adequate tissue concentrations.[1]
What patents protect nitrofurantoin macrocrystalline?
No material U.S. patent barrier is expected to prevent generic competition for nitrofurantoin macrocrystalline.
Patent and exclusivity position
| Rights category |
Commercial position |
| Core composition patent |
Expired |
| Original formulation patents |
Expired or commercially nonblocking |
| FDA new-drug exclusivity |
Expired |
| Pediatric exclusivity |
Not a current barrier |
| Orphan exclusivity |
Not applicable to the core product |
| Orange Book blocking patent |
No meaningful originator barrier expected |
| Generic ANDA pathway |
Established |
| Manufacturing know-how |
Relevant to quality and supply, but not a broad market-exclusion right |
Any remaining patents would generally concern a specific formulation, process, packaging configuration or combination product rather than the active ingredient itself. Such rights would not recreate originator exclusivity for standard nitrofurantoin macrocrystalline capsules.
What is the Orange Book status of nitrofurantoin macrocrystalline?
The Orange Book is relevant primarily for identifying reference-listed drugs and approved generic equivalents. Nitrofurantoin macrocrystalline products are mature multisource products, and the key competitive issue is therapeutic equivalence rather than patent certification.
Generic applicants may file Paragraph IV certifications if an Orange Book-listed patent is identified for a particular reference product. For conventional nitrofurantoin macrocrystalline capsules, the principal market risk does not arise from active Paragraph IV litigation. It arises from price erosion, manufacturer exits, raw-material shortages and substitution toward nitrofurantoin monohydrate/macrocrystals.
Are companies challenging nitrofurantoin macrocrystalline patents?
The market does not have a major current Paragraph IV campaign comparable to branded blockbusters. Generic manufacturers already compete in the category. Litigation risk is more likely to involve:
- Product-quality or bioequivalence disputes.
- Manufacturing-site compliance.
- Contract and supply agreements.
- False-marketing or antitrust claims.
- Narrow formulation patents for modified-release products.
How large is the nitrofurantoin market?
Public market-research estimates for global nitrofurantoin revenue vary substantially because reports differ on whether they include:
- Nitrofurantoin macrocrystalline only.
- Monohydrate/macrocrystals and oral suspension.
- Hospital and retail channels.
- Branded and generic sales.
- International markets with different formulations and pricing.
The market is best characterized as a mature, globally distributed generic antibacterial category rather than a high-growth branded pharmaceutical franchise.
Market structure
| Segment |
Demand profile |
Pricing profile |
| Acute uncomplicated cystitis |
Largest use case |
Low-cost generic, high prescription turnover |
| Recurrent UTI prophylaxis |
Smaller volume, longer duration |
More exposure to safety and stewardship controls |
| Pediatric use |
Limited |
Formulation and dosing constraints |
| Oral suspension |
Niche |
Higher unit economics, lower volume |
| Hospital use |
Limited relative to outpatient use |
Often restricted by local protocols |
| International markets |
Variable |
Sensitive to reimbursement and local manufacturing |
The largest demand driver is outpatient treatment of uncomplicated lower urinary-tract infection. Nitrofurantoin is favored in many guidelines because it has limited collateral activity against non-urinary flora and remains active against many extended-spectrum beta-lactamase-producing E. coli isolates, although local resistance data control empiric suitability.[6]
What is the market outlook for nitrofurantoin macrocrystalline?
The five-year outlook is stable to modestly positive in volume and weak to moderate in nominal revenue. Unit demand should remain supported by urinary-tract infection prevalence, antimicrobial stewardship and resistance to some alternative oral antibiotics. Revenue growth will be constrained by generic pricing and substitution between macrocrystalline and monohydrate/macrocrystals products.
Base-case projection
| Period |
Expected volume trend |
Expected revenue trend |
Main drivers |
| 2025-2026 |
Low single-digit growth |
Flat to low single-digit growth |
Stable cystitis prescribing, generic competition |
| 2027-2028 |
Low single-digit growth |
Low single-digit growth |
Resistance-driven preference, population aging |
| 2029-2030 |
Flat to low single-digit growth |
Flat to moderate growth |
Pricing pressure offset by demand and supply consolidation |
This projection assumes no major safety signal, no broad withdrawal of nitrofurantoin from guidelines and continued availability of active pharmaceutical ingredient.
Upside factors
- Rising resistance to trimethoprim-sulfamethoxazole and fluoroquinolones.
- Greater outpatient management of uncomplicated cystitis.
- Expanded use in older adults where renal function permits treatment.
- Manufacturing consolidation that improves supply reliability.
- Increased use of susceptibility-directed therapy against resistant E. coli.
Downside factors
- Greater use of methenamine for recurrent UTI prevention.
- Stronger restrictions on chronic prophylaxis.
- Pulmonary, hepatic or neurologic safety signals.
- Renal-function restrictions that reduce prescribing in older adults.
- Shortages of nitrofurantoin API or finished capsules.
- Further price compression among generic manufacturers.
How does nitrofurantoin macrocrystalline compare with competing UTI drugs?
| Drug or class |
Main advantage |
Main limitation |
Competitive relationship |
| Nitrofurantoin |
Narrow urinary activity and continued usefulness against many resistant isolates |
Not suitable for pyelonephritis; toxicity with chronic exposure |
Core comparator for uncomplicated cystitis |
| Trimethoprim-sulfamethoxazole |
Familiar, inexpensive oral option |
Resistance can be high; drug interactions and allergy concerns |
Substitute where local susceptibility is favorable |
| Fosfomycin |
Single-dose oral treatment; useful against selected resistant organisms |
Variable efficacy and higher cost in some markets |
Alternative for uncomplicated cystitis |
| Fluoroquinolones |
Broad tissue penetration |
Stewardship restrictions and serious adverse effects |
Generally avoided for uncomplicated cystitis when alternatives exist |
| Beta-lactams |
Familiar and widely available |
Variable efficacy and resistance |
Used when first-line agents are unsuitable |
| Methenamine hippurate |
Non-antibiotic prophylaxis |
Not a treatment for acute bacterial cystitis |
Long-term prophylaxis substitute |
Nitrofurantoin macrocrystalline competes most directly with trimethoprim-sulfamethoxazole, fosfomycin and beta-lactams. It competes with methenamine mainly in recurrent-UTI prevention, not in acute treatment.
What generic entry risks exist for nitrofurantoin macrocrystalline?
Generic entry risk is already realized rather than prospective. The product has multiple suppliers and no meaningful remaining compound exclusivity. Commercial risk for an incumbent manufacturer comes from additional ANDA approvals, tender losses and price reductions.
Generic launch scenarios
| Scenario |
Likely market effect |
| New standard-dose capsule entrant |
Immediate price pressure and share fragmentation |
| New oral-suspension entrant |
Limited category impact because the segment is small |
| New modified-release entrant |
Greater substitution from macrocrystalline capsules |
| API shortage |
Temporary price increase and allocation risk |
| Manufacturer withdrawal |
Short-term supply disruption, followed by replacement entrants |
| Bioequivalence or quality failure |
Recall exposure and accelerated share transfer |
The strongest competitive defenses are manufacturing reliability, regulatory compliance, wholesaler access and cost-efficient API sourcing. Brand recognition has limited defensive value in a mature generic market.
What manufacturing and intellectual-property barriers affect the product?
Nitrofurantoin macrocrystalline has low legal barriers but moderate operational barriers.
Manufacturing considerations
Manufacturers must control:
- Particle size and crystal form.
- Content uniformity.
- Dissolution and release behavior.
- Capsule-fill consistency.
- Impurity and degradation profiles.
- API supply-chain continuity.
- Bioequivalence to the applicable reference product.
For macrocrystalline products, particle characteristics can affect dissolution, gastrointestinal tolerability and pharmacokinetic comparability. These technical requirements can delay approval or create quality risks even when no enforceable patent blocks entry.
What is the litigation and settlement outlook?
A major branded-generic patent settlement is unlikely to shape the standard nitrofurantoin macrocrystalline market. The product’s litigation profile is more likely to involve:
- Product liability claims related to pulmonary or hepatic injury.
- Generic-drug quality or recall disputes.
- Regulatory enforcement involving manufacturing controls.
- Contract disputes between suppliers and distributors.
- Competition-law claims involving shortages or market allocation.
The absence of a significant patent estate reduces Paragraph IV settlement risk. It does not eliminate operational litigation or safety-related exposure.
What is the commercial outlook for investors and generic manufacturers?
Nitrofurantoin macrocrystalline is a defensive, low-growth generic opportunity. Its value lies in recurring outpatient demand and clinical persistence, not exclusivity or premium pricing.
Investment profile
| Factor |
Assessment |
| Demand durability |
High |
| Revenue growth |
Low |
| Margin potential |
Low to moderate, depending on supply position |
| Patent protection |
Minimal |
| Regulatory risk |
Moderate |
| Clinical differentiation |
Low |
| Resistance support |
Favorable but geographically variable |
| Supply-chain risk |
Moderate |
| Biosimilar risk |
Not applicable |
| Brand-switching risk |
High |
The most attractive commercial positions are likely to involve reliable API sourcing, low-cost manufacturing, differentiated packaging, oral suspension capability or strong access to outpatient pharmacy channels. A standalone investment thesis based on patent protection or rapid revenue expansion is weak.
Key Takeaways
- Nitrofurantoin macrocrystalline is a mature, FDA-approved generic for susceptible uncomplicated lower urinary-tract infection.
- No meaningful U.S. compound patent or exclusivity barrier remains.
- Contemporary clinical research focuses on comparative effectiveness, recurrent UTI prevention, antimicrobial resistance and long-term safety.
- Nitrofurantoin remains commercially relevant because of outpatient cystitis demand and continued activity against many resistant uropathogens.
- Market growth should remain low, with generic price pressure limiting revenue expansion.
- The principal threats are substitution by monohydrate/macrocrystals products, methenamine use for prophylaxis, safety concerns and supply disruption.
- Manufacturing quality, API access and distribution are more important than patent rights in determining competitive performance.
FAQs about nitrofurantoin macrocrystalline
Is nitrofurantoin macrocrystalline still considered a first-line UTI treatment?
Yes. It remains a commonly recommended option for acute uncomplicated cystitis when the organism is likely to be susceptible and the patient does not have suspected pyelonephritis or a contraindication.
Does nitrofurantoin macrocrystalline treat kidney infections?
No. Its limited renal-tissue and serum penetration makes it unsuitable for pyelonephritis and other systemic urinary infections.
Is Macrodantin still patent-protected?
No material patent protection is expected to block generic competition for conventional nitrofurantoin macrocrystalline capsules.
Is nitrofurantoin macrocrystalline interchangeable with Macrobid?
They contain related nitrofurantoin formulations but are not automatically interchangeable on a milligram-for-milligram or dosing-frequency basis. Product-specific labeling and pharmacy substitution rules apply.
Does nitrofurantoin have biosimilar competition?
No. Biosimilar regulation applies to biologic products. Nitrofurantoin is a small-molecule antibacterial marketed through conventional generic-drug pathways.
References
- U.S. Food and Drug Administration. (2023). Macrodantin (nitrofurantoin macrocrystals) prescribing information.
- Harding, C., Mossop, H., Homer, T., et al. (2022). Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: A multicentre, open-label, randomised, non-inferiority trial. The BMJ, 376, e068229.
- American College of Obstetricians and Gynecologists. (2023). Urinary tract infections in pregnant individuals. ACOG Clinical Consensus.
- Medicines and Healthcare products Regulatory Agency. (2023). Nitrofurantoin: reminder of the risks of pulmonary and hepatic adverse drug reactions. Drug Safety Update.
- American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081.
- Infectious Diseases Society of America and European Society for Microbiology and Infectious Diseases. (2011). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women. Clinical Infectious Diseases, 52(5), e103-e120.
